Anti-20S proteasome autoantibodies inhibit proteasome stimulation by proteasome activator PA28

Arthritis and Rheumatism

Volumn 54, Issue 7, 2006, Pages 2175-2183

  Brychcy, Michael ^a   Kuckelkorn, Ulrike ^a   Hausdorf, Gert ^a   Egerer, Karl ^a   Kloetzel, Peter M ^a   Burmester, Gerd R ^a   Feist, Eugen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; ENZYME ACTIVATOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PEPTIDE; POLYCLONAL ANTIBODY; PROTEASOME;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODY SPECIFICITY; AUTOANTIBODIES; ENZYME ACTIVATION; HOMEOSTASIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MUSCLE PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; SJOGREN'S SYNDROME;

EID: 33745890229     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21970     Document Type: Article

References (33)

1. Casiano CA, Tan EM. Recent developments in the understanding of antinuclear autoantibodies. Int Arch Allergy Immunol 1996;111:308-13.
2. Arribas J, Luz Rodriguez M, Alvarez-Do Forno R, Castano JG. Autoantibodies against the multicatalytic proteinase in patients with systemic lupus erythematosus. J Exp Med 1991;173:423-7.
3. Feist E, Dorner T, Kuckelkorn U, Schmidtke G, Micheel B, Hiepe F, et al. The proteasome α-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J Exp Med 1996;184:1313-8.
4. Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993;11:213-44.
5. Coux O, Tanaka K, Goldberg AL. Structure and function of the 20S and 26S proteasomes. Ann Rev Biochem 1996;65:801-47.
6. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997;386:463-71.
7. Seemuller E, Lupas A, Stock D, Lowe J, Huber R, Baumeister W. Proteasome from Thermoplasma acidophilum: a threonine protease. Science 1995;268:579-82.
8. Seufert W, Jentsch S. In vivo function of the proteasome in the ubiquitin pathway. EMBO J 1992;11:3077-80.
9. Boes B, Hengel H, Ruppert T, Multhaup G, Koszinowski UH, Kloetzel PM. Interferon γ stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med 1994;179:901-9.
10. Aki M, Shimbara N, Takashina M, Akiyama K, Kagawa S, Tamura T, et al. Interferon-γ induces different subunit organizations and functional diversity of proteasomes. J Biochem 1994;115:257-69.
11. Nandi D, Jiang H, Monaco JJ. Identification of MECL-1 (LMP10) as the third IFN-γ-inducible proteasome subunit. J Immunol 1996;156:2361-4.
12. Kuckelkorn U, Frentzel S, Kraft R, Kostka S, Groettrup M, Kloetzel PM. Incorporation of major histocompatibility complex-encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-γ. Eur J Immunol 1995;25:2605-11.
13. Hallermalm K, Seki K, Wei C, Castelli C, Rivoltini L, Kiessling R, et al. Tumor necrosis factor-α induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. Blood 2001;98:1108-15.
14. Rivett AJ, Mason GG, Murray RZ, Reidlinger J. Regulation of proteasome structure and function. Mol Biol Rep 1997;24:99-102.
15. Ahn JY, Tanahashi N, Akiyama K, Hisamatsu H, Noda C, Tanaka K, et al. Primary structures of two homologous subunits of PA28, a γ-interferon- inducible protein activator of the 20S proteasome. FEBS Lett 1995;366:37-42.
16. Matsushita M, Takasaki Y, Takeuchi K, Yamada H, Matsudaira R, Hashimoto H. Autoimmune response to proteasome activator 28α in patients with connective tissue diseases. J Rheumatol 2004;31:252-9.
17. Feist E, Kuckelkorn U, Dorner T, Donitz H, Scheffler S, Hiepe F, et al. Autoantibodies in primary Sjögren's syndrome are directed against proteasomal subunits of the α and β type. Arthritis Rheum 1999;42:697-702.
18. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
19. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
20. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
21. Vitali C, Bombardieri S, Moutsopoulos HM, Coll J, Gerli R, Matron PY, et al, and the European Study Group on Diagnostic Criteria for Sjogren's Syndrome. Assessment of the European classification criteria for Sjogren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. Ann Rheum Dis 1996;55:116-21.
22. Egerer K, Kuckelkorn U, Rudolph PE, Ruckert JC, Dorner T, Burmester GR, et al. Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol 2002;29:2045-52.
23. Kuckelkorn U, Knuehl C, Boes-Fabian B, Drung I, Kloetzel PM. The effect of heat shock on 20S/26S proteasomes. Biol Chem 2000;381:1017-23.
24. O'Farrell PZ, Goodman HM, O'Farrell PH. High resolution two-dimensional electrophoresis of basic as well as acidic proteins. Cell 1977;12:1133-41.
25. Dahlmann B, Ruppert T, Kuehn L, Merforth S, Kloetzel PM. Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J Mol Biol 2000;303:643-53.
26. Rechsteiner M, Hill CP. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 2005;15:27-33.
27. Whitby FG, Masters EI, Kramer L, Knowlton JR, Yao Y, Wang CC, et al. Structural basis for the activation of 20S proteasomes by 11S regulators. Nature 2000;408:115-20.
28. Murata S, Udono H, Tanahashi N, Hamada N, Watanabe K, Adachi K, et al. Immunoproteasome assembly and antigen presentation in mice lacking both PA28α and PA28β. EMBO J 2001;20:5898-907.
29. Zaiss DM, Standera S, Holzhutter H, Kloetzel P, Sijts AJ. The proteasome inhibitor PI31 competes with PA28 for binding to 20S proteasomes. FEBS Lett 1999;457:333-8.
30. Seeger M, Ferrell K, Frank R, Dubiel W. HIV-1 rat inhibits the 20 S proteasome and its 11 S regulator-mediated activation. J Biol Chem 1997;272:8145-8.
31. Stohwasser R, Holzhutter HG, Lehmann U, Henklein P, Kloetzel PM. Hepatitis B virus HBx peptide 116-138 and proteasome activator PA28 compete for binding to the proteasome α4/MC6 subunit. Biol Chem 2003;384:39-49.
32. Zaiss DM, Standera S, Kloetzel PM, Sijts AJ. PI31 is a modulator of proteasome formation and antigen processing. Proc Natl Acad Sci U S A 2002;99:14344-9.
33. Blade J, Cibeira MT, Rosinol L. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Acta Oncol 2005;44:440-8.